Mallinckrodt plc to Report Earnings Results for First Quarter 2025

Rhea-AI Summary

Mallinckrodt (MNK) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:30 a.m. ET on the same day.

Investors can participate through multiple channels, including a live call registration system, an audio-only webcast, or through the company's Investor Relations webpage.

DUBLIN, April 10, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025. 

A conference call for investors will begin at 8:30 a.m. ET and can be accessed as follows:

• Live Call Participant Registration (including dial-in):  https://register-conf.media-server.com/register/BI59a8cb021a314d8683b4822df03f9735

• Audio-Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/tkagfrhx

• On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Investor Relations Contact

Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-earnings-results-for-first-quarter-2025-302424998.html

SOURCE Mallinckrodt plc

FAQ

When will Mallinckrodt (MNK) release Q1 2025 earnings?

Mallinckrodt will release Q1 2025 earnings on Tuesday, May 6, 2025.

What time is Mallinckrodt's (MNK) Q1 2025 earnings call?

The earnings conference call is scheduled for 8:30 a.m. ET on May 6, 2025.

How can investors access Mallinckrodt's (MNK) Q1 2025 earnings call?

Investors can access the call through live call registration, audio-only webcast, or the company's Investor Relations webpage.

Where can I find the webcast link for Mallinckrodt's (MNK) Q1 2025 earnings?

The audio webcast can be accessed at edge.media-server.com/mmc/p/tkagfrhx or through Mallinckrodt's IR website.